Recombinant Human WT1 protein, His-tagged

• Cat.No.: WT1-17H
• Product Overview: Recombinant Human WT1(Leu310~Leu449) fused with His tag at N-terminal was expressed in E. coli.

Specification

• Description: This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
• Source: E. coli
• Species: Human
• Tag: His
• Form: PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300
• Molecular Mass: 46.5kDa
• Protein length: Leu310~Leu449
• Endotoxin: <1.0EU per 1µg (determined by the LAL method)
• Purity: > 90%
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
  If bio-activity of the protein is needed, please check active protein
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months.
• Reconstitution: Reconstitute in PBS or others.

Gene Information

• Gene Name: WT1 Wilms tumor 1 [ Homo sapiens ]
• Official Symbol: WT1
• Synonyms: WT1; Wilms tumor 1; GUD; Wilms tumor protein; AWT1; WAGR; WIT 2; amino-terminal domain of EWS|last three zinc fingers of the DNA-binding domain of WT1; WT33; NPHS4; WIT-2; EWS-WT1
• Gene ID: 7490
• mRNA Refseq: NM_000378
• Protein Refseq: NP_000369
• MIM: 607102
• UniProt ID: P19544
• Chromosome Location: 11p13
• Pathway: Regulation of Telomerase, organism-specific biosystem; Transcriptional misregulation in cancer, organism-specific biosystem; Transcriptional misregulation in cancer, conserved biosystem
• Function: C2H2 zinc finger domain binding; RNA binding; RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; double-stranded DNA binding; metal ion binding; protein binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; sequence-specific DNA binding transcription factor activity; transcription regulatory region DNA binding; zinc ion binding

Reviews

10/10/2020

It has been widely employed in protein electron microscopy structure analysis, where it has demonstrated remarkable efficacy.

10/25/2019

Broad applicability make it a valuable asset for a wide range of research endeavors.

05/07/2017

Researchers can rely on the WT1 Protein to deliver reliable and reproducible results, facilitating robust data interpretation and scientific advancements.

Q&As

What therapeutic strategies are being explored for cancers with abnormal WT1 expression?

Targeted therapies and immunotherapies aimed at inhibiting or modulating WT1 expression are being investigated for their potential in cancer treatment.

In what other cancers is the WT1 protein targeted for diagnostic purposes?

Apart from Wilms' tumor, WT1 is examined in leukemia, mesothelioma, and some solid tumors as a diagnostic marker.

Can WT1 be a target for personalized cancer therapy?

Yes, understanding the WT1 status in a patient's cancer can guide the development of personalized treatment plans, potentially improving outcomes.

Are there any ongoing clinical trials focused on the WT1 protein and cancer?

Yes, there are several clinical trials exploring the role of WT1 as a therapeutic target and its potential in cancer treatment.

How does the WT1 protein contribute to the prognosis of cancer patients?

High levels of WT1 expression are often associated with poor prognosis in various cancers, indicating a more aggressive disease course.